Entero Therapeutics, Inc.(ENTO)Earnings, Financials & Key Ratios

ENTO•NASDAQ

$2.85

Price updated Jun 20, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryImmunology and Inflammation Therapies

AboutFirst Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Show more

Revenue$36K
EBITDA-$7M-21355.6%
Net Income-$7M+63.7%
EPS (Diluted)-4.16+20.9%
EBITDA Margin-19539.98%
Operating Margin-19539.98%
Net Margin-18078.34%
ROE-14.92%+74.6%

ENTO Price & Volume

Entero Therapeutics, Inc. (ENTO) stock price & volume — 10-year historical chart

Loading chart...

Clinical Asset Acquisition Masks Severe Liquidity Constraints

Investment Thesis • Updated 2025Q4

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity and dilution

Key Thesis Takeaways

Entero Therapeutics faces a critical juncture as its reliance on the latiglutenase pipeline necessitates significant capital, yet the company maintains a precarious financial position with only $899,784 in cash as of 2025Q4.
The firm's strategy of aggressive asset acquisition, evidenced by an $8.7 million outlay in 2025Q4, has resulted in a $208.8 million accumulated deficit and creates substantial dilution risk for shareholders.
Investors should monitor the company's ability to secure non-dilutive funding, as the current burn rate and lack of commercial revenue suggest an imminent need for capital restructuring.

Verdict Logic

the company's cash reserves of $899,784 are insufficient to support ongoing clinical development, creating an immediate and severe risk of shareholder dilution.

ENTO Growth Metrics

Entero Therapeutics, Inc. (ENTO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM63.71%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-51.27%

Return on Capital

10 Years-463.68%

5 Years-380.66%

3 Years-161.97%

Last Year-15.52%

Peers Comparison

Key metrics vs top competitors for Entero Therapeutics, Inc. (ENTO)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ENTOEntero Therapeutics, Inc.Current	$2.85	$9.58M	-0.54	—	-18078.34%	-14.92%	—
RCKTRocket Pharmaceuticals, Inc.	$3.37	$367.98M	-1.68	—	—	-70.79%	—
ARWRArrowhead Pharmaceuticals, Inc.	$80.50	$11.34B	-6598.36	23258.15%	-48.38%	-55.09%	—
PTGXProtagonist Therapeutics, Inc.	$121.63	$7.82B	-59.33	-89.41%	-648.27%	-17.76%	—
CDXSCodexis, Inc.	$2.33	$211.79M	-4.66	18.61%	-40.96%	-68.09%	—
AGENAgenus Inc.	$3.15	$131.17M	-926.47	10.37%	52.16%	—	—